Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3927]

Osimertinib plus gefitinib for treatment of EGFR-mutated non-small cell lung...

Dr Julia Rotow - Dana Farber Cancer Institute, Boston, USA

Osimertinib plus gefitinib for treatment of EGFR-mutated non-small cell lung cancer ( Dr Julia Rotow - Dana Farber Cancer Institute, Boston, USA )

METex14 SAs (MET exon 14 skipping alterations) in non-small cell lung cancer

Prof Mark Awad - Dana Farber Cancer Institute, Boston, USA

METex14 SAs (MET exon 14 skipping alterations) in non-small cell lung cancer ( Prof Mark Awad - Dana Farber Cancer Institute, Boston, USA )

PARP inhibitors in prostate cancer: Choices of tests and how to test?

Dr Kim Chi and Dr Alexander Wyatt

PARP inhibitors in prostate cancer: Choices of tests and how to test? ( Dr Kim Chi and Dr Alexander Wyatt )

ASCO 2020: Breast cancer roundup

Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy

ASCO 2020: Breast cancer roundup ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )

FORTE trial: Minimal residual disease evaluation in newly diagnosed multiple...

Dr Stefania Oliva - GIMEMA, European Myeloma Network, Italy

FORTE trial: Minimal residual disease evaluation in newly diagnosed multiple myeloma ( Dr Stefania Oliva - GIMEMA, European Myeloma Network, Italy )

The PANDA study: Combining panitumumab with FOLFOX or 5FU in elderly patients...

Dr Sara Lonardi - Istituto Oncologico Veneto, Padua, Italy

The PANDA study: Combining panitumumab with FOLFOX or 5FU in elderly patients with RAS-BRAF WT metastatic colorectal cancer ( Dr Sara Lonardi - Istituto Oncologico Veneto, Padua, Italy )

Comparing pevonedistat plus azacitidine versus azacitidine alone in patients...

Prof Lionel Ades - Hôpital Saint-Louis, Paris, France

Comparing pevonedistat plus azacitidine versus azacitidine alone in patients with higher-risk MDS/CMML or low-blast AML ( Prof Lionel Ades - Hôpital Saint-Louis, Paris, France )

ASCO 2020 prostate cancer highlights

Prof Karim Fizazi, Prof Axel Merseburger, Dr Kim Chi and Prof Amit Bahl

ASCO 2020 prostate cancer highlights ( Prof Karim Fizazi, Prof Axel Merseburger, Dr Kim Chi and Prof Amit Bahl )

COVID-19: Optimising supportive care during active cancer treatment

Dr Paul Cornes - Comparative Outcomes Group, Bristol, UK

COVID-19: Optimising supportive care during active cancer treatment ( Dr Paul Cornes - Comparative Outcomes Group, Bristol, UK )

ASCO 2020: Updates in renal cancer

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA

ASCO 2020: Updates in renal cancer ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )

TROPHIMMUN: Avelumab for gestational trophoblastic tumours resistant to...

Prof Benoit You - Hospices Civils de Lyon, Lyon, France

TROPHIMMUN: Avelumab for gestational trophoblastic tumours resistant to monochemotherapy ( Prof Benoit You - Hospices Civils de Lyon, Lyon, France )

KEYNOTE-177 results: Pembrolizumab versus chemotherapy for patients with MSI-H...

Prof Thierry Andre - Sorbonne University and Saint-Antoine Hospital, Paris...

KEYNOTE-177 results: Pembrolizumab versus chemotherapy for patients with MSI-H/dMMR colorectal cancer ( Prof Thierry Andre - Sorbonne University and Saint-Antoine Hospital, Paris, France )

More from ecancer